Yeztugo, a twice-yearly shot, could be the catalyst for stopping a recent spike in new HIV diagnoses. It's now available in ...

Milestone Pharmaceuticals Inc. is a strong buy after a 37% drop post-Cardamyst FDA approval. Click for this updated look at ...